[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse UBE2N

Summary
SymbolUBE2N
Nameubiquitin-conjugating enzyme E2N
Aliases UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm
Domain PF00179 Ubiquitin-conjugating enzyme
Function

The UBE2V1-UBE2N and UBE2V2-UBE2N heterodimers catalyze the synthesis of non-canonical 'Lys-63'-linked polyubiquitin chains. This type of polyubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Acts together with the E3 ligases, HLTF and SHPRH, in the 'Lys-63'-linked poly-ubiquitination of PCNA upon genotoxic stress, which is required for DNA repair. Appears to act together with E3 ligase RNF5 in the 'Lys-63'-linked polyubiquitination of JKAMP thereby regulating JKAMP function by decreasing its association with components of the proteasome and ERAD. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes.

> Gene Ontology
 
Biological Process GO:0000209 protein polyubiquitination
GO:0000724 double-strand break repair via homologous recombination
GO:0000725 recombinational repair
GO:0000726 non-recombinational repair
GO:0000729 DNA double-strand break processing
GO:0002218 activation of innate immune response
GO:0002220 innate immune response activating cell surface receptor signaling pathway
GO:0002221 pattern recognition receptor signaling pathway
GO:0002223 stimulatory C-type lectin receptor signaling pathway
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002753 cytoplasmic pattern recognition receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006282 regulation of DNA repair
GO:0006289 nucleotide-excision repair
GO:0006301 postreplication repair
GO:0006302 double-strand break repair
GO:0006303 double-strand break repair via nonhomologous end joining
GO:0006310 DNA recombination
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0016570 histone modification
GO:0016574 histone ubiquitination
GO:0030522 intracellular receptor signaling pathway
GO:0031056 regulation of histone modification
GO:0031058 positive regulation of histone modification
GO:0031349 positive regulation of defense response
GO:0031396 regulation of protein ubiquitination
GO:0031398 positive regulation of protein ubiquitination
GO:0033182 regulation of histone ubiquitination
GO:0035872 nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway
GO:0038093 Fc receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045739 positive regulation of DNA repair
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051438 regulation of ubiquitin-protein transferase activity
GO:0051443 positive regulation of ubiquitin-protein transferase activity
GO:0070423 nucleotide-binding oligomerization domain containing signaling pathway
GO:0070534 protein K63-linked ubiquitination
GO:0070911 global genome nucleotide-excision repair
GO:1902275 regulation of chromatin organization
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903322 positive regulation of protein modification by small protein conjugation or removal
GO:1905269 positive regulation of chromatin organization
GO:2001020 regulation of response to DNA damage stimulus
GO:2001022 positive regulation of response to DNA damage stimulus
Molecular Function GO:0004842 ubiquitin-protein transferase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0031625 ubiquitin protein ligase binding
GO:0032182 ubiquitin-like protein binding
GO:0043130 ubiquitin binding
GO:0044389 ubiquitin-like protein ligase binding
GO:0061630 ubiquitin protein ligase activity
GO:0061631 ubiquitin conjugating enzyme activity
GO:0061650 ubiquitin-like protein conjugating enzyme activity
GO:0061659 ubiquitin-like protein ligase activity
Cellular Component GO:0000151 ubiquitin ligase complex
GO:0031371 ubiquitin conjugating enzyme complex
GO:0031372 UBC13-MMS2 complex
GO:0035370 UBC13-UEV1A complex
> KEGG and Reactome Pathway
 
KEGG hsa04120 Ubiquitin mediated proteolysis
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-1280218: Adaptive Immune System
R-HSA-983168: Antigen processing
R-HSA-1169410: Antiviral mechanism by IFN-stimulated genes
R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5607764: CLEC7A (Dectin-1) signaling
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-5693606: DNA Double Strand Break Response
R-HSA-5693532: DNA Double-Strand Break Repair
R-HSA-73894: DNA Repair
R-HSA-202424: Downstream TCR signaling
R-HSA-8866654: E3 ubiquitin ligases ubiquitinate target proteins
R-HSA-2871837: FCERI mediated NF-kB activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-5696395: Formation of Incision Complex in GG-NER
R-HSA-69481: G2/M Checkpoints
R-HSA-69473: G2/M DNA damage checkpoint
R-HSA-5696399: Global Genome Nucleotide Excision Repair (GG-NER)
R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA)
R-HSA-5693538: Homology Directed Repair
R-HSA-937041: IKK complex recruitment mediated by RIP1
R-HSA-937039: IRAK1 recruits IKK complex
R-HSA-975144: IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
R-HSA-1169408: ISG15 antiviral mechanism
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-913531: Interferon Signaling
R-HSA-446652: Interleukin-1 signaling
R-HSA-450321: JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
R-HSA-450294: MAP kinase activation in TLR cascade
R-HSA-392499: Metabolism of proteins
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-168638: NOD1/2 Signaling Pathway
R-HSA-5693571: Nonhomologous End-Joining (NHEJ)
R-HSA-5696398: Nucleotide Excision Repair
R-HSA-168643: Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
R-HSA-597592: Post-translational protein modification
R-HSA-5693607: Processing of DNA double-strand break ends
R-HSA-8852135: Protein ubiquitination
R-HSA-5693565: Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
R-HSA-449147: Signaling by Interleukins
R-HSA-445989: TAK1 activates NFkB by phosphorylation and activation of IKKs complex
R-HSA-202403: TCR signaling
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-975110: TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-450302: activated TAK1 mediates p38 MAPK activation
Summary
SymbolUBE2N
Nameubiquitin-conjugating enzyme E2N
Aliases UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between UBE2N and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolUBE2N
Nameubiquitin-conjugating enzyme E2N
Aliases UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of UBE2N in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.47; FDR: 0.01650 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolUBE2N
Nameubiquitin-conjugating enzyme E2N
Aliases UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of UBE2N in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1130.507
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3410.895
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0520.978
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1540.712
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3870.812
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8370.68
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1340.735
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2410.896
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.010.996
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0610.972
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0190.994
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0990.11
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of UBE2N in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUBE2N
Nameubiquitin-conjugating enzyme E2N
Aliases UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UBE2N. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUBE2N
Nameubiquitin-conjugating enzyme E2N
Aliases UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UBE2N. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UBE2N.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUBE2N
Nameubiquitin-conjugating enzyme E2N
Aliases UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UBE2N. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUBE2N
Nameubiquitin-conjugating enzyme E2N
Aliases UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of UBE2N expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUBE2N
Nameubiquitin-conjugating enzyme E2N
Aliases UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between UBE2N and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUBE2N
Nameubiquitin-conjugating enzyme E2N
Aliases UbcH-ben; UBC13; MGC8489; ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13); ubiquitin-conjugatin ......
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting UBE2N collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.